Trial Profile
Efficacy of cabozantinib in patients with advanced non-clear cell renal cell carcinoma: A multicenter retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Mar 2019
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 28 Feb 2019 Results assessing cabozantinib in advanced non-clear-cell renal cell carcinoma published in the Lancet Oncology
- 25 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology